ArticleMolecular cancer therapeutics2026
Targeting pancreatic cancer with adenoviral vectors equipped with transgenes.
Article in Molecular cancer therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and current therapeutics provide limited benefits to patients. Desmoplasia and the highly immunosuppressive tumor microenvironment (TME) play a huge role in PDAC being elusive to current therapeutics. Here, we strategically selected four transgenes to express from adenovirus vectors to target desmoplasia and the highly immunosuppressive TME in PDAC: interferon gamma (IFNγ), extracellular domain of transforming growth factor beta receptor 2 (sTGFβRII), interleukin 7 (IL7), and the extracellular domain of T-cell Immunoglobulin and Mucin domain-containing protein 3 (sTIM3). We used an immunocompetent syngeneic mouse model harboring tumors derived from KPC cells, a common mouse pancreatic cancer cell line, to test the anti-tumor effects of our transgene-expressing Ad vectors. We showed that all four transgenes elicited significant anti-tumor effects and shifted the tumors to a more immunogenic profile by increasing intratumoral expression of immune activation proteins and infiltration of anti-tumor immune cells. Furthermore, inhibition of desmoplasia was observed in three of four proteins. Of the four transgenes analyzed, IFNγ and sTGFβRII induced the greatest anti-tumor results and were combined in a single Ad vector. This dual-expressing Ad vector elicited the greatest anti-tumor effect, increase in immunogenicity, decrease in fibrosis, and showed abscopal effects. These results provide insight into how the analyzed transgenes can favorably alter the TME in pancreatic cancer patients and show encouraging potential when combined with other therapeutic regimens.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.